IP Library Granted Patent US 11,903,922
Granted Patent B2
US 11,903,922 · App. 16/928,200 · Granted Feb 20, 2024

Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

Inventors: Christopher Rinsch (Morges, CH); William Blanco-Bose (La Croix, CH); Bernard Schneider (Pully, CH); Charles Thomas (Dijon, FR); Carmen Sandi (Bremblens, CH); Johan Auwerx (Buchillon, CH); Penelope Andreux (Eclepens, CH); Richardus Houtkooper (Weesp, NL); Eija Pirinen (Lausanne, CH); Laurent Mouchiroud (Morges, CH); David Genoux (Lausanne, CH)
Assignee: Amazentis SA
A61K31/366A23L33/105A61K9/0014A61K9/0053A61K9/0056A61K31/352A61K31/7048A61K36/185A23V2002/00Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,903,922
App. No.
16/928,200
Granted
Feb 20, 2024
Kind
B2
Abstract

Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.

Claims (22)

1. A method of treating a disease or a condition selected from the group consisting of stress, a stress-induced disorder, a stress-related disorder, and an anxiety disorder, comprising:

administering to a subject in need thereof a therapeutically effective amount of a urolithin or a salt thereof,

wherein the stress-induced or stress-related disorder is stress-induced or stress-related cognitive deficit, stress-induced or stress-related cognitive dysfunction, stress-induced or stress-related mood disorder, or stress-induced or stress-related anxiety.

2. The method of claim 1 , wherein the disease or condition is stress, a stress-induced disorder, or a stress-related disorder.

3. The method of claim 2 , wherein the disease or condition is stress.

4. The method of claim 3 , wherein the stress is chronic stress.

5. The method of claim 2 , wherein the disease or condition is a stress-induced disorder or a stress-related disorder.

6. The method of claim 1 , wherein the disease or condition is an anxiety disorder.

7. The method of claim 6 , wherein the anxiety disorder is selected from the group consisting of generalized anxiety disorder, panic disorder, panic disorder with agoraphobia, agoraphobia, social anxiety disorder, obsessive-compulsive disorder, and post-traumatic stress disorder.

8. The method of claim 1 , wherein the urolithin is urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof.

9. The method of claim 8 , wherein the urolithin is urolithin A.

10. The method of claim 1 , wherein the subject is a mammal.

11. The method of claim 10 , wherein the mammal is a human.

12. The method of claim 1 , wherein the urolithin is administered orally.

13. The method of claim 1 , wherein the urolithin is administered parenterally.

14. The method of claim 1 , wherein the urolithin is administered as a pharmaceutical composition, a medical food, a functional food, a food additive, a dietary supplement, a food product, or a nutritional supplement.

15. The method of claim 1 , wherein the urolithin is urolithin A; the subject is a mammal; the mammal is a human; and the urolithin is administered orally.

16. The method of claim 15 , wherein the urolithin is administered as a pharmaceutical composition, a medical food, a functional food, a food additive, a dietary supplement, a food product, or a nutritional supplement.

17. The method of claim 3 , wherein the urolithin is urolithin A; the subject is a mammal; the mammal is a human; and the urolithin is administered orally.

18. The method of claim 17 , wherein the urolithin is administered as a pharmaceutical composition, a medical food, a functional food, a food additive, a dietary supplement, a food product, or a nutritional supplement.

19. The method of claim 5 , wherein the urolithin is urolithin A; the subject is a mammal; the mammal is a human; and the urolithin is administered orally.

20. The method of claim 19 , wherein the urolithin is administered as a pharmaceutical composition, a medical food, a functional food, a food additive, a dietary supplement, a food product, or a nutritional supplement.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2020
From: ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
To: AMAZENTIS SA
Reel/Frame 054048/0669 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2020
From: RINSCH, CHRISTOPHER L.; BLANCO-BOSE, WILLIAM
To: AMAZENTIS SA
Reel/Frame 054076/0369 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2020
From: SCHNEIDER, BERNARD; THOMAS, CHARLES; SANDI, CARMEN; AUWERX, JOHAN; ANDREUX, PENELOPE; HOUTKOOPER, RICHARDUS; PIRINEN, EIJA; MOUCHIROUD, LAURENT; GENOUX, DAVID
To: ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
Reel/Frame 054076/0562 →
Continuity (5)
Continuation 15218663 · Jul 25, 2016
Division 14644912 · Mar 11, 2015
Division 13336841 · Dec 23, 2011
Provisional Application 61426957 · Dec 23, 2010
Related Publication 20210059982A1 · Mar 4, 2021
Cited By (4)
US 12,310,943 US 12,544,358 US 12,576,064 US 12,576,065